JOIN US

THE

CUREWORKS

MODEL

Immunotherapy

Innovation

------

Unprecedented CAR T experience and technologies, including process expertise to accelerate translation from “bench to bedside.”

Consultation &

Training

------

Members leverage individual and collective expertise around CAR T-cell therapies, clinical trials management, grants, regulatory affairs, and manufacturing.

Facilitating

Manufacturing

------

Members gain  access to GMP clinical cell manufacturing to produce treatments for their patients, reducing the need for capital investment for network members.

Outreach &

Engagement

------

Management of external communications with constituent communities, government agencies, media, and other stakeholders.

Clinical Trial

Coordination

------

Expanded access to a diverse participant pool, streamlined enrollment process, multi-site trial strategy, and regulatory agency expertise.

A SHARED COMMITMENT TO A COMPLEX SCIENCE.

Curing pediatric cancer is such a big and complex challenge, it’s unrealistic to think that any one pediatric center can get the job done alone. By working together in a coordinated way, we can accomplish more, with greater benefits, at lower costs.

As a member, your institution will be able to participate in the CureWorks pipeline and provide innovative immunotherapies directly to your patients. This allows you to treat more patients locally, while redefining the standard of care globally. Members benefit from access to an array of technologies, data, and expertise, including clinical trial coordination and manufacturing of individual treatments.

CAPABILITIES

We are building an organization and a pipeline that will continuously push the bounds of scientific discovery in pursuit of cures. We see a world where there is no chemo, no radiation, and finally, no pediatric cancer.

SEE OUR PIPELINE

 

29,000

______

square-feet of

manufacturing space

(in 2020)

 

500

______

GMP grade engineered cell products per year

(in 2020)

 

Trials currently

in pipeline

______

11

 

 

 

BECOME A MEMBER

We are looking for institutions that share our commitment to expanding access to these promising cures for children. To learn more about becoming a participating institution, please contact us at info@cureworks.org

 

ACADEMIC PUBLICATIONS

Learn more about our science and progress.

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility

Clinical Cancer Research

Neuroblastoma is the most common extracranial solid tumor of childhood with a heterogeneous clinical course. While neuroblastomas with favorable biology spontaneously regress or differentiate without therapeutic intervention, neuroblastomas with unfavorable biology often fatally progress despite intensive multimodal therapy.

READ MORE

 

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

The New England Journal of Medicine

Glioblastoma, an aggressive primary brain tumor, is among the most lethal of human cancers. We present evidence of the potential therapeutic benefit of adoptive T-cell therapy against glioblastoma with the use of CAR-engineered T cells targeting IL13Rα2, a glioma-associated antigen linked to a reduced rate of survival.

READ MORE

 

Designing chimeric antigen receptors to effectively and safely target tumors

Science Direct

The adoptive transfer of T cells engineered to express artificial chimeric antigen receptors CARs) that target a tumor cell surface molecule has emerged as an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors.

READ MORE

 

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Pub Med Central

CD19-specific chimeric antigen receptor (CAR)–expressing autologous T cells administered after lymphodepleting chemotherapy can induce clinical remissions in B-lineage malignancies, including refractory pediatric acute lymphoblastic leukemia (ALL), irrespective of disease burden or anatomic dissemination.

READ MORE

 

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

Read the latest announcements

about our collaboration.

JOIN US

A SHARED COMMITMENT TO A COMPLEX SCIENCE.

Curing pediatric cancer is such a big and complex challenge, it’s unrealistic to think that any one pediatric center can get the job done alone. By working together in a coordinated way, we can accomplish more, with greater benefits, at lower costs.

As a member, your institution will be able to participate in the CureWorks pipeline and provide innovative immunotherapies directly to your patients. This allows you to treat more patients locally, while redefining the standard of care globally. Members benefit from access to an array of technologies, data, and expertise, including clinical trial coordination and manufacturing of individual treatments.

 

 

THE

CUREWORKS

MODEL

Immunotherapy

Innovation

------

Unprecedented CAR T experience and technologies, including process expertise to accelerate translation from “bench to bedside.”

 

Facilitating

Manufacturing

------

Members gain access to GMP facility to produce treatments for their patients at a reduced level of capital investment.

 

Clinical Trial

Coordination

------

Expanded access to diverse participant pool, streamlined enrollment process, multi-site trial strategy, and regulatory agency expertise.

 

 

Outreach &

Engagement

------

Management of external communications with constituent communities, government agencies, media, and other stakeholders.

 

 

Consultation &

Training

------

Members leverage individual and collective expertise around CAR T-cell therapies, clinical trials management, grants, regulatory affairs, and manufacturing.

 

 

 



CAPABILITIES

We are building an organization and a pipeline that will continuously push the bounds of scientific discovery in pursuit of cures. We see a world where there is no chemo, no radiation, and finally, no pediatric cancer.

SEE OUR PIPELINE

 

29,000

______

square-feet of

manufacturing space

(in 2020)

 

500

______

GMP grade engineered
cell products per year

(in 2020)

 

11

______

Trials currently in pipeline

 

 

 

 

 

 

BECOME A MEMBER

We are looking for institutions that share our commitment to expanding access to these promising cures for children. To learn more about becoming a participating institution, please contact us at info@cureworks.org

 

 

 

 

 

ACADEMIC PUBLICATIONS

Learn more about our science and progress.

Clinical Cancer Research

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility

Neuroblastoma is the most common extracranial solid tumor of childhood with a heterogeneous clinical course. While neuroblastomas with favorable biology spontaneously regress or differentiate without therapeutic intervention, neuroblastomas with unfavorable biology often fatally progress despite intensive multimodal therapy.

READ MORE

 

The New England Journal of Medicine

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Glioblastoma, an aggressive primary brain tumor, is among the most lethal of human cancers. We present evidence of the potential therapeutic benefit of adoptive T-cell therapy against glioblastoma with the use of CAR-engineered T cells targeting IL13Rα2, a glioma-associated antigen linked to a reduced rate of survival.

READ MORE

 

Science Direct

Designing chimeric antigen receptors to effectively and safely target tumors

The adoptive transfer of T cells engineered to express artificial chimeric antigen receptors CARs) that target a tumor cell surface molecule has emerged as an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors.

READ MORE

 

Pub Med Central

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

CD19-specific chimeric antigen receptor (CAR)–expressing autologous T cells administered after lymphodepleting chemotherapy can induce clinical remissions in B-lineage malignancies, including refractory pediatric acute lymphoblastic leukemia (ALL), irrespective of disease burden or anatomic dissemination.

READ MORE

 

 

For information about clinical trials in your area, please contact
your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

Read the latest announcements

about our collaboration.

CureWorks logo A new way to better cures

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

Read the latest announcements

about our collaboration.

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

CureWorks logo A new way to better cures

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

Read the latest announcements

about our collaboration.

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

Read the latest announcements

about our collaboration.

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

CureWorks logo A new way to better cures

For information about clinical trials in your area, please contact
your child’s physician or visit clinicaltrials.gov

Read the latest announcements

about our collaboration.

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.